Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007150044 - GENETIC MODELS FOR STRATIFICATION OF CANCER RISK

Publication Number WO/2007/150044
Publication Date 27.12.2007
International Application No. PCT/US2007/071932
International Filing Date 22.06.2007
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/16
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
16Primer sets for multiplex assays
C12Q 2600/172
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
172Haplotypes
Applicants
  • INTERGENETICS, INC. [US]/[US] (AllExceptUS)
  • OKLAHOMA MEDICAL RESEARCH FOUNDATION [US]/[US] (AllExceptUS)
  • RALPH, David [US]/[US] (UsOnly)
  • ASTON, Christopher [AU]/[US] (UsOnly)
  • JUPE, Eldon [US]/[US] (UsOnly)
Inventors
  • RALPH, David
  • ASTON, Christopher
  • JUPE, Eldon
Agents
  • HIGHLANDER, Steven, L.
Priority Data
60/805,69223.06.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) GENETIC MODELS FOR STRATIFICATION OF CANCER RISK
(FR) MODÈLES GÉNÉTIQUES UTILISÉS POUR LA STRATIFICATION DES RISQUES DE CANCER
Abstract
(EN)
The present invention provides new methods for the assessment of cancer risk in the general population. These methods utilize particular alleles of selected genes, namely ACCalpha, ADPRT, CYPlAl, CYPlBl, GADD45, HLAh, 1CAM5, KLKlO, KLK2, MP0463, MSH6, PGR, RAD51L3, STK15 AND TFR, and particular combinations of genotypes, to identify individuals with increased or decreased risk of breast cancer. In addition, personal history measures such as age and race are used to further refine the analysis. Using such methods, it is possible to reallocate healthcare costs in cancer screening to patient subpopulations at increased cancer risk. It also permits identification of candidates for cancer prophylactic treatment.
(FR)
La présente invention concerne de nouveaux procédés utilisables pour l'évaluation des risques de cancer dans la population générale. Ces procédés utilisent des allèles particuliers de gènes sélectionnés et des combinaisons particulières de génotypes afin d'identifier les individus présentant un risque accru ou diminué de cancer du sein. En outre, des valeurs faisant partie des antécédents personnels, telles que l'âge et la race, sont utilisées pour raffiner encore l'analyse. Grâce à ces procédés, il est possible de réallouer les dépenses médicales associées au dépistage du cancer en direction de sous-populations de patients souffrant d'un risque de cancer accru. Cela permet également d'identifier les candidats à l'administration d'un traitement prophylactique contre le cancer.
Latest bibliographic data on file with the International Bureau